• About
  • Privacy Policy
  • Terms
  • Contact
Friday, January 27, 2023
Financial Eye News
  • Home
  • Markets
    • Stock Market News
    • Commodities
    • Forex
    • Renewables
  • Cryptocurrency
    • Ultimate Guide to Crypto
  • Business
    • News
    • Companies
    • Technology
    • Climate
    • Politics
  • Reports
    • Ultimate Guide to Crypto
  • VideosNew
No Result
View All Result
  • Home
  • Markets
    • Stock Market News
    • Commodities
    • Forex
    • Renewables
  • Cryptocurrency
    • Ultimate Guide to Crypto
  • Business
    • News
    • Companies
    • Technology
    • Climate
    • Politics
  • Reports
    • Ultimate Guide to Crypto
  • VideosNew
No Result
View All Result
Financial Eye News
No Result
View All Result

Samsung Biologics capitalises on pandemic boom to expand in US and Europe

March 21, 2022
in Companies
Reading Time: 3 mins read
49 2
ADVERTISEMENT

Samsung Biologics, the biopharmaceutical unit of South Korea’s Samsung Group, is seeking to build its first plants in the US and Europe as it rebalances its global supply chains following the pandemic.

The world’s largest contract drugmaker, which produces for other global pharmaceutical companies, is cash-rich two years into the pandemic, posting a 35 per cent jump in 2021 revenue. Its manufacturing order backlogs are up 25 per cent to $7.5bn on surging demand for coronavirus treatments offered by US drugmaker Eli Lilly and the UK’s GSK and AstraZeneca.

John Lim, the company’s chief executive, told the Financial Times that the company seeks to build overseas plants to be closer to its main customers and meet surging demand for contract manufacturing.

“The Covid situation has highlighted more of the need to diversify and risk manage, particularly around supply chain management. It has also highlighted the need for doing things quick,” said Lim, who has been head of the company since December 2020.

He said demand for Covid antibody treatments were exceeding supply because of growing orders from US customers, though demand for Covid vaccines decreased recently because of the Omicron variant. The company added that it has not yet experienced any significant supply disruption as a result of the war in Ukraine.

The company signed a “fill and finish” deal with Moderna last May and began producing vials of Moderna’s mRNA vaccines in September. From April, it will also start producing GreenLight Bioscience’s mRNA vaccine candidate, which is in third-stage clinical trials.

The pandemic has helped the company rapidly expand its product portfolio. It has diversified from its focus on monoclonal antibodies — molecules engineered to fight cancer and autoimmune diseases — to offer products including cell and gene therapies and next-generation vaccines using mRNA, pitting it against its Swiss rival Lonza Group and Germany’s Boehringer Ingelheim.

Lim said biosimilars, which are lower priced than branded products, are making faster penetration in Europe than in the US, citing more complicated patent and pricing issues in the US.

“But the US will start to pick up as well because all the health systems globally are under more pressure to reduce expenses and make [treatments] more available to patients,” he said.

Samsung Biologics expects to double its market share for large-scale monochrome antibody production to 40 per cent next year once its $1.4bn fourth plant in Songdo comes online in October.

Global sales of biological medicines are estimated at $419bn this year, still smaller than their chemical counterparts at $542bn, but the market is forecast to grow 35 per cent to $564bn by 2026, according to research firm Evaluate Pharma.

But contract manufacturing of biological drugs requires heavier investments and a demanding production process that Lin said was similar to semiconductors because it should not be contaminated by bacteria.

Samsung Biologics has also been on the acquisition hunt. It recently agreed to buy Biogen’s 49.9 per cent stake in their joint venture Bioepis for $2.3bn to reinforce its biosimilar business, which is seen as a stepping stone to its long-term goal of making its own new drugs.

Source: Financial Times

ADVERTISEMENT
Share6Tweet4Share1SendShareSend

Related Posts

Companies

Bame workers report pervasive discrimination in finserv

December 5, 2022
Companies

Rail industry enters last-ditch talks to avoid UK Christmas disruption

December 5, 2022
Companies

Glencore: dirty business provides an embarrassment of riches

December 5, 2022
Companies

Trucks: Tesla Semi pulls ahead as start-up rivals crash

December 5, 2022
Companies

Vodafone needs a radical new chief to bring about real change

December 5, 2022
Companies

Vodafone: departure of Nick Read should accelerate restructuring

December 5, 2022

Popular Stories

  • AIG to launch cut-price IPO of life and asset management unit

    48 shares
    Share 19 Tweet 12
  • EY boss targets $10bn boost from Silicon Valley tie-ups after break-up

    32 shares
    Share 13 Tweet 8
  • Tesla delays plan to restore Shanghai output to pre-lockdown levels -memo

    32 shares
    Share 13 Tweet 8
  • TV production giant Banijay to go public via Arnault-backed Spac

    30 shares
    Share 12 Tweet 8
  • Nio to Invest $32.8M Building R&D Labs in Shanghai By Financial Eye

    30 shares
    Share 12 Tweet 8
ADVERTISEMENT

Latest News

Taylor Swift Fans Sue Ticketmaster’s Parent Company

December 5, 2022

Fisker trades down following price cut at Citi By Financial Eye

December 5, 2022

UAW president faces run-off election as reformers make gains

December 5, 2022

Felipe Valls, 89, Whose Cuban Restaurant Became a Political Hub, Dies

December 5, 2022

Longroad buys 98-MW solar farm in California

December 5, 2022
Facebook Twitter LinkedIn

Financial Eye is one of the most trusted news sources for Financial News, global news and local USA news, we provide the news from the most trusted sources.

LEARN MORE »

Recent News

  • Taylor Swift Fans Sue Ticketmaster’s Parent Company
  • Fisker trades down following price cut at Citi By Financial Eye
  • UAW president faces run-off election as reformers make gains

Sections

  • Business
  • Climate
  • Commodities
  • Companies
  • Cryptocurrency
  • Cryptocurrency
  • Forex
  • Green Energy
  • Latest Financial News
  • News
  • Politics
  • Stock Market News
  • Technology
  • Videos

© 2022 Financial Eye News Media

No Result
View All Result
  • Home
  • Markets
    • Stock Market News
    • Commodities
    • Forex
    • Renewables
  • Cryptocurrency
    • Ultimate Guide to Crypto
  • Business
    • News
    • Companies
    • Technology
    • Climate
    • Politics
  • Reports
    • Ultimate Guide to Crypto
  • Videos

© 2022 Financial Eye News Media

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Subscribe To Our Daily News Round-Up.

The top ten most-read stories direct to your inbox

You have Successfully Subscribed!

You have Successfully Subscribed!

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.